Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced its participation in the Cowen 41^st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. ET, where CEO Ted White will present a business overview. Interested parties can access a live webcast through provided links, with a replay available for 30 days post-event. The company focuses on dermatology therapeutics, developing treatments for conditions like molluscum contagiosum and warts. Its key product candidates include VP-102 and VP-103, with a worldwide licensing agreement for LTX-315.

Positive

• Participation in Cowen Health Care Conference may enhance visibility and investor interest.
• Focus on unmet medical needs in dermatology with promising product candidates.

Negative

• None.

WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Cowen 41^st Annual Health Care Conference on Tuesday, March 2, 2021, at 11:50 a.m. ET.

Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/cowen81/vrca/1949628.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@troutgroup.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@troutgroup.com

FAQ

What is Verrica Pharmaceuticals planning to present at the Cowen Conference?

Verrica Pharmaceuticals will present a business overview at the Cowen 41st Annual Health Care Conference on March 2, 2021.

What are the main product candidates being developed by Verrica Pharmaceuticals?

Verrica is developing VP-102 for molluscum contagiosum and warts, and VP-103 for plantar warts.

Where can I access the webcast of Verrica's presentation?

The webcast can be accessed via the links provided in the press release or on Verrica's website in the Investors section.

How long will the webcast replay be available after the conference?

The webcast replay will be available for 30 days after the event.

What is LTX-315 and how is it related to Verrica Pharmaceuticals?

LTX-315 is a product Verrica licensed for dermatologic oncology, developed in collaboration with Lytix Biopharma AS.